BWAY vs. XAIR, DCTH, ANIK, TMCI, OSUR, NVRO, SGHT, CERS, GUTS, and OBIO
Should you be buying BrainsWay stock or one of its competitors? The main competitors of BrainsWay include Beyond Air (XAIR), Delcath Systems (DCTH), Anika Therapeutics (ANIK), Treace Medical Concepts (TMCI), OraSure Technologies (OSUR), Nevro (NVRO), Sight Sciences (SGHT), Cerus (CERS), Fractyl Health (GUTS), and Orchestra BioMed (OBIO). These companies are all part of the "surgical & medical instruments" industry.
Beyond Air (NASDAQ:XAIR) and BrainsWay (NASDAQ:BWAY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.
Beyond Air has a net margin of 0.00% compared to Beyond Air's net margin of -4.83%. Beyond Air's return on equity of -3.98% beat BrainsWay's return on equity.
31.5% of Beyond Air shares are owned by institutional investors. Comparatively, 30.1% of BrainsWay shares are owned by institutional investors. 19.0% of Beyond Air shares are owned by insiders. Comparatively, 19.0% of BrainsWay shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
BrainsWay has higher revenue and earnings than Beyond Air. BrainsWay is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.
Beyond Air has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, BrainsWay has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.
BrainsWay received 19 more outperform votes than Beyond Air when rated by MarketBeat users. However, 68.75% of users gave Beyond Air an outperform vote while only 64.95% of users gave BrainsWay an outperform vote.
Beyond Air presently has a consensus target price of $10.75, indicating a potential upside of 818.80%. BrainsWay has a consensus target price of $13.00, indicating a potential upside of 107.34%. Given BrainsWay's stronger consensus rating and higher possible upside, equities research analysts plainly believe Beyond Air is more favorable than BrainsWay.
In the previous week, BrainsWay had 10 more articles in the media than Beyond Air. MarketBeat recorded 11 mentions for BrainsWay and 1 mentions for Beyond Air. Beyond Air's average media sentiment score of 0.55 beat BrainsWay's score of 0.00 indicating that BrainsWay is being referred to more favorably in the news media.
Summary
BrainsWay beats Beyond Air on 9 of the 16 factors compared between the two stocks.
Get BrainsWay News Delivered to You Automatically
Sign up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BrainsWay Competitors List
Related Companies and Tools
